News › Clinical Practice, Industry News, Patient Care

FDA OKs Describe Patch for Use with All Tattoo Removal Lasers

December 12, 2017

The new FDA clearance also extends the shelf life of the Patch from two years to three years.
The Patch, which is placed over tattoos prior to removal with a laser, allows physicians to treat tattoos more efficiently by enabling rapid multiple laser passes in a single treatment session.
The Patch was previously cleared in April 2015 for use with the 755 nm QS Alexandrite laser, which is effective in removal of tattoos with blue or black ink. This clearance now includes use of the 532, 694, 755 and 1064 nm standard Q-Switched (QS) lasers and 532, 755, 785 and 1064 nm standard picosecond lasers in Fitzpatrick Skin Type I-III patients. The expanded indication allows the Patch to be used with all commonly used lasers, providing the capability to remove tattoos across a spectrum of colors.  
Read more at Aesthetics Wire >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Allergan Aesthetics’ Skinvive by Juvéderm Receives FDA Approval for the Improvement of Neck Appearance
    • Obagi Medical Announces FDA Approval of Obagi saypha ChIQ Injectable Hyaluronic Acid Gel
    • MedSafe Becomes Gold Vendor Affiliate with the American Med Spa Association
    • FDA Approves First New Sunscreen Ingredient in 20 Years
    • Allergan Aesthetics Releases ‘The Aesthetics Evolution: What Consumers Really Want’ Highlighting Consumer Motivations and Expectations in Aesthetics